Physician profile
Haresh Jani
NPI 1760486583
$944.79
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $12.66 · 2022: $13.89 · 2023: $16.18 · 2024: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $128.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $194.07 | 2019-2024 | |
| Pfizer INC. | $134.92 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $110.15 | 2019 | |
| Astellas Pharma US INC | $95.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $74.75 | 2019 | |
| Novo Nordisk INC | $73.66 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.25 | 2019 | |
| Lantheus Medical Imaging, INC. | $47.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.50 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $37.01 | 2019 | |
| Amgen INC. | $25.90 | 2019 | |
| Abbott Laboratories | $20.83 | 2019 | |
| Glaxosmithkline, LLC. | $14.96 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.18 | 2019 | |
| Lilly USA, LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haresh Jani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.